1009 Rituximab in Systemic Lupus Erythematosus in Pediatric Patients

Neurobrucellosis in systemic lupus erythematosus

Background: Brucellosis is a zoonotic infection which is endemic in many countries. It is a multisystem disease which may present with a broad spectrum of clinical manifestations and complications. Neurobrucellosis is an uncommon complication of brucellosis. Case presentation: A 25-year-old woman with a history of lupus for 5 months referred to the emergency ward of Shahid Beheshti Hosp...

T Lymphocyte Apoptosis in Systemic Lupus Erythematosus Patients

Objective(s):  Apoptosis is a tightly regulated process and plays a crucial role in autoimmune diseases. Because abnormalities in apoptosis are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), in present study we studied the apoptosis in T lymphocytes from Iranian SLE patientsat protein and gene expression levels for some molecules which are involved in apopt...

Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus

Background & aim: Pregnant women with systemic lupus erythematosus (SLE) are considered to be at high risk regarding fetal complications and adverse outcomes. The aim of this study was to evaluate the fetal outcomes in pregnant women with the SLE. Methods: This retrospective study was conducted on a total of 125 patients with the SLE referred to the Clinic and Department of Rheumatology of Imam...

Pediatric systemic lupus erythematosus

Rituximab in systemic lupus erythematosus and lupus nephritis.

Treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have high associated morbidity and mortality. Side effects, particularly from long-term corticosteroid usage, limit patient adherence, with subsequent impacts on treatment efficacy. In addition, a subset of patients with SLE/LN fails to respond to current standard immunotherapy. There is an urgent need to develop ...